Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.43 |
| ▸ | ADH5 | P11766 | 4/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12263260 | 0.83 | ALDH1A1 (0.48) | HPGDADORA2AADORA2B | |
| SCHEMBL5344758 | 0.80 | HPGDS (0.53) | CHEK1ADH5MKNK1MKNK2IDO1 | |
| SCHEMBL12263446 | 0.80 | P2RX3 (0.43) | HPGDCHEK1ADH5MKNK1MKNK2 | |
| SCHEMBL7821311 | 0.76 | ADH5 (0.54) | ADH5MAP4K4IDO1 | |
| SCHEMBL12263289 | 0.75 | HPGD (0.46) | HPGD | |
| SCHEMBL31735528 | 0.72 | HPGD (0.46) | HPGDCHEK1ADH5ADORA2AADORA2B | |
| SCHEMBL30948515 | 0.72 | FNTB (0.45) | — | |
| SCHEMBL24268069 | 0.71 | SYK (0.45) | — | |
| SCHEMBL28758928 | 0.70 | TBXAS1 (0.50) | — | |
| SCHEMBL25099090 | 0.69 | CYP11B2 (0.55) | HPGDCHEK1ADH5MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022208-B2 | Benzene derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-09-20 | — | — | US | disclosed |
| US-8022208-B2 | Benzene derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20090054352-A1 | BENZENE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-02-26 | — | — | US | disclosed |
| US-20090054352-A1 | BENZENE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-1947086-A1 | BENZENE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054352-A1 | BENZENE DERIVATIVE OR SALT THEREOF | F12, F2, SERPINC1 | HPGD 582/4885CHEK1 3532/4885ADH5 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.